Role of rs6923761 gene variant in glucagon-like peptide 1 receptor in basal GLP-1 levels, cardiovascular risk factor and serum adipokine levels in naïve type 2 diabetic patients

2014 ◽  
Vol 38 (2) ◽  
pp. 143-147 ◽  
Author(s):  
D. A. de Luis ◽  
R. Aller ◽  
O. Izaola ◽  
R. Bachiller
Keyword(s):  
Risk Factor ◽  
Cardiovascular Risk ◽  
Diabetic Patients ◽  
Gene Variant ◽  
Type 2 Diabetic Patients ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Type 2 Diabetic

scholarly journals The role of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes

2017 ◽  
Vol 5 (2) ◽  
pp. 79-89 ◽  
Author(s):  
Erin St Onge ◽  
Shannon Miller ◽  
Elizabeth Clements ◽  
Lindsay Celauro ◽  
Ke’la Barnes
Keyword(s):  
Type 2 Diabetes ◽  
New Combination ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Potential Weight ◽  
Type 2 Diabetic

Abstract The role of GLP-1 agonists in the treatment of type 2 diabetes have been shown to be viable options for add-on therapy in diabetic patients, as well as potential monotherapy options. With six available GLP-1 agents, and new combination products in the pipeline, they are a promising drug class for type 2 diabetic patients, especially due to their extended dosing interval and potential weight loss benefits.

scholarly journals Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients

2001 ◽  
Vol 86 (8) ◽  
pp. 3717-3723 ◽  
Author(s):  
Mai-Britt Toft-Nielsen ◽  
Mette B. Damholt ◽  
Sten Madsbad ◽  
Linda M. Hilsted ◽  
Thomas E. Hughes ◽  
...  
Keyword(s):  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document